RecruitingPhase 1NCT02390752
Phase I Trial of TURALIO(R) (Pexidartinib, PLX3397) in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) and Tenosynovial Giant Cell Tumor ...
Studying Neurofibroma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- National Cancer Institute (NCI)
- Principal Investigator
- Rosandra N Kaplan, M.D.National Cancer Institute (NCI)
- Intervention
- TURALIO(R)(drug)
- Enrollment
- 54 enrolled
- Eligibility
- 3-35 years · All sexes
- Timeline
- 2015 – 2026
Study locations (1)
- National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT02390752 on ClinicalTrials.govOther trials for Neurofibroma
Additional recruiting or active studies for the same condition.
- ACTIVE NOT RECRUITINGNANCT06175637Observational Study to Evaluate the Effect and Safety of Selumetinib in Pediatric Patients With NF1-PNsAstraZeneca
- ACTIVE NOT RECRUITINGNANCT05891847Non-interventional Study of Patients With PN NF1 Starting Selumetinib in RussiaAstraZeneca
- RECRUITINGNANCT05199376Evaluation of Percutaneous Cryotherapy in the Treatment of Plexiform Neurofibromas and Unresectable Neurofibromas in Neurofibromatosis Type 1Centre Leon Berard
- ACTIVE NOT RECRUITINGPHASE2NCT03962543MEK Inhibitor Mirdametinib (PD-0325901) in Patients With Neurofibromatosis Type 1 Associated Plexiform NeurofibromasSpringWorks Therapeutics, Inc.